Why the study?
Do dihydropyridine calcium channel blockers improve outcomes in patients with hypertension and cardiovascular disease?
Do dihydropyridine calcium channel blockers improve outcomes in patients with hypertension and cardiovascular disease?
This review highlights recent evidence supporting the efficacy of dihydropyridine calcium channel blockers for hypertension and cardiovascular disease, countering previous negative claims.
Supports reevaluating dihydropyridine CCBs in hypertension; leaves open confirmation by updated meta-analyses before guideline changes.
Recent evidence supports a central role for calcium channel blockers (CCBs), and in particular the dihydropyridine (DHP) agents, in the treatment of hypertension and cardiovascular disease (CVD). We review here the findings of recent trials, systematic reviews and meta-analyses that rebut those of the single, yet widely-publicised, earlier unfavourable meta-analysis.
No takes yet. Share an insight, caveat, or question.
Messerli et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: